Golden Biotechnology Past Earnings Performance
Past criteria checks 0/6
Golden Biotechnology's earnings have been declining at an average annual rate of -0.02%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 7.9% per year.
Key information
-0.02%
Earnings growth rate
4.8%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 7.9% |
| Return on equity | -157.6% |
| Net Margin | -659.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Golden Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 57 | -379 | 172 | 207 |
| 31 Mar 24 | 60 | -370 | 175 | 205 |
| 31 Dec 23 | 63 | -362 | 179 | 203 |
| 30 Sep 23 | 125 | -284 | 181 | 193 |
| 30 Jun 23 | 186 | -207 | 184 | 184 |
| 31 Mar 23 | 202 | -240 | 177 | 231 |
| 31 Dec 22 | 218 | -272 | 170 | 278 |
| 30 Sep 22 | 162 | -352 | 170 | 288 |
| 30 Jun 22 | 107 | -432 | 171 | 297 |
| 31 Mar 22 | 94 | -438 | 171 | 281 |
| 31 Dec 21 | 82 | -444 | 171 | 265 |
| 30 Sep 21 | 82 | -456 | 174 | 266 |
| 30 Jun 21 | 81 | -468 | 177 | 267 |
| 31 Mar 21 | 85 | -430 | 177 | 231 |
| 31 Dec 20 | 89 | -391 | 178 | 195 |
| 30 Sep 20 | 92 | -330 | 173 | 159 |
| 30 Jun 20 | 95 | -268 | 168 | 123 |
| 31 Mar 20 | 89 | -277 | 170 | 133 |
| 31 Dec 19 | 83 | -285 | 173 | 142 |
| 30 Sep 19 | 81 | -311 | 178 | 163 |
| 30 Jun 19 | 78 | -336 | 183 | 184 |
| 31 Mar 19 | 85 | -340 | 183 | 193 |
| 31 Dec 18 | 91 | -344 | 183 | 202 |
| 30 Sep 18 | 91 | -343 | 179 | 203 |
| 30 Jun 18 | 91 | -342 | 175 | 204 |
| 31 Mar 18 | 97 | -335 | 182 | 193 |
| 31 Dec 17 | 104 | -327 | 189 | 181 |
| 30 Sep 17 | 127 | -300 | 206 | 156 |
| 30 Jun 17 | 150 | -274 | 223 | 130 |
| 31 Mar 17 | 145 | -259 | 214 | 119 |
| 31 Dec 16 | 139 | -244 | 205 | 107 |
| 30 Sep 16 | 113 | -255 | 194 | 110 |
| 30 Jun 16 | 87 | -266 | 184 | 114 |
| 31 Mar 16 | 104 | -256 | 196 | 108 |
| 31 Dec 15 | 120 | -246 | 207 | 102 |
| 30 Sep 15 | 124 | -211 | 194 | 89 |
| 30 Jun 15 | 128 | -175 | 181 | 75 |
| 31 Mar 15 | 117 | -185 | 170 | 88 |
| 31 Dec 14 | 105 | -195 | 160 | 100 |
| 30 Sep 14 | 118 | -210 | 175 | 107 |
| 30 Jun 14 | 130 | -225 | 190 | 114 |
| 31 Mar 14 | 148 | -197 | 200 | 92 |
| 31 Dec 13 | 165 | -168 | 209 | 69 |
Quality Earnings: 4132 is currently unprofitable.
Growing Profit Margin: 4132 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4132 is unprofitable, and losses have increased over the past 5 years at a rate of 0.02% per year.
Accelerating Growth: Unable to compare 4132's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4132 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 4132 has a negative Return on Equity (-157.58%), as it is currently unprofitable.